Galectin Therapeutics Inc (NASDAQ: GALT) shares fell 46% to $1.34, after the company disclosed that its Phase 2a clinical (NASH-FX) trial did not meet either primary or secondary endpoints. Share volume was 5.5 million more than 11 times its all-day average
